Law360, New York (December 17, 2008, 12:00 AM ET) -- Lupin Ltd. has become the latest company to settle patent litigation with Schering Corp. over a planned generic version of the allergy medication Clarinex.
Lupin and Schering both said Wednesday that under the settlement, Lupin will license the Clarinex patents from Schering and will be able to launch its generic version on July 1, 2012. The two companies have filed a joint stipulation of dismissal in the U.S. District Court for the District of New Jersey.
Mumbai, India-based Lupin had filed an abbreviated new drug application...
Lupin Settles Clarinex Suit With Schering
To view the full article, take a free trial now.
